Agreement with Robotic Biology Institute to Jointly Sell an Integrated Solution for Cell Culture Automation and Optimization
Epistra, Inc. has agreed with Robotic Biology Institute, Inc. (hereinafter RBI) to jointly sell an integrated solution for cell culture automation and optimization.
According to OECD projections, the global regenerative medicine market is expected to reach approximately 1 trillion yen by 2030.
Solution Overview
This solution combines the automation of cell culture experiments using RBI’s humanoid robot “LabDroid Mahoro” with the optimization of culture conditions using Epistra’s automated experimental design AI “Epistra Accelerate.”
- LabDroid “Mahoro”: A humanoid robot system with two arms that possesses dexterity equivalent to humans, executing cell culture operations with precision and high reproducibility
- Epistra Accelerate: An AI system designed to discover optimal culture conditions with fewer experimental trials
The memorandum of understanding was signed on January 1, 2023.
Company Information
- Epistra, Inc.: Founded March 2018, Minato-ku, Tokyo
- Robotic Biology Institute, Inc.: Koto-ku, Tokyo
Related Articles
Won Grand Prix in the 7th IP BASE AWARD Startup Category Hosted by the Japan Patent Office
On March 3, 2026, Epistra Inc. won the Grand Prix in the startup category at the '7th IP BASE AWARD' ceremony hosted by the Japan Patent Office.
Jikkenigaku Special Issue 'AI and Data-Driven Drug Discovery Research' Published — CTO Tsuzuki Authors Chapter on AI-Driven Drug Target Discovery
In 'Jikkenigaku Special Issue: AI and Data-Driven Drug Discovery Research' published by Yodosha, our CTO Taku Tsuzuki authored a chapter on AI-driven knowledge mining for drug target discovery.
Speaking Engagement: Delivered Keynote at the 10th Cell Manufacturing Kotozukuri Symposium
On March 4, 2026, CEO Yosuke Ozawa delivered a keynote speech on optimizing cell manufacturing processes using AI and robotics at the '10th Cell Manufacturing Kotozukuri Symposium' hosted by Osaka University.